These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24201751)

  • 1. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
    Szkandera J; Stotz M; Absenger G; Stojakovic T; Samonigg H; Kornprat P; Schaberl-Moser R; Alzoughbi W; Lackner C; Ress AL; Seggewies FS; Gerger A; Hoefler G; Pichler M
    Br J Cancer; 2014 Jan; 110(1):183-8. PubMed ID: 24201751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.
    Stotz M; Szkandera J; Seidel J; Stojakovic T; Samonigg H; Reitz D; Gary T; Kornprat P; Schaberl-Moser R; Hoefler G; Gerger A; Pichler M
    PLoS One; 2014; 9(8):e104730. PubMed ID: 25133546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
    Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
    Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan.
    Inoue D; Ozaka M; Matsuyama M; Yamada I; Takano K; Saiura A; Ishii H
    Jpn J Clin Oncol; 2015 Jan; 45(1):61-6. PubMed ID: 25341546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.
    Stotz M; Gerger A; Eisner F; Szkandera J; Loibner H; Ress AL; Kornprat P; AlZoughbi W; Seggewies FS; Lackner C; Stojakovic T; Samonigg H; Hoefler G; Pichler M
    Br J Cancer; 2013 Jul; 109(2):416-21. PubMed ID: 23799847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients.
    Szkandera J; Gerger A; Liegl-Atzwanger B; Absenger G; Stotz M; Samonigg H; Maurer-Ertl W; Stojakovic T; Ploner F; Leithner A; Pichler M
    Br J Cancer; 2013 Oct; 109(9):2316-22. PubMed ID: 24084772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer.
    Stotz M; Szkandera J; Stojakovic T; Seidel J; Samonigg H; Kornprat P; Schaberl-Moser R; Seggewies F; Hoefler G; Gerger A; Pichler M
    Clin Chem Lab Med; 2015 Feb; 53(3):499-506. PubMed ID: 25389993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.
    Asamer E; Szkandera J; Gibiser P; Lembeck AL; Stojakovic T; Kornprat P; Lackner C; Winder T; Schlick K; Stöger H; Gerger A; Pichler M; Stotz M
    Wien Klin Wochenschr; 2018 Oct; 130(19-20):569-574. PubMed ID: 30132196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
    J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.
    Szkandera J; Stotz M; Eisner F; Absenger G; Stojakovic T; Samonigg H; Kornprat P; Schaberl-Moser R; Alzoughbi W; Ress AL; Seggewies FS; Gerger A; Hoefler G; Pichler M
    PLoS One; 2013; 8(11):e78225. PubMed ID: 24223776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
    Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
    BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
    Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
    Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
    Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
    Nurmi AM; Mustonen H; Haglund C; Seppänen H
    Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
    La Torre M; Nigri G; Cavallini M; Mercantini P; Ziparo V; Ramacciato G
    Ann Surg Oncol; 2012 Sep; 19(9):2917-23. PubMed ID: 22488099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma.
    Arima K; Yamashita YI; Hashimoto D; Nakagawa S; Umezaki N; Yamao T; Tsukamoto M; Kitano Y; Yamamura K; Miyata T; Okabe H; Ishimoto T; Imai K; Chikamoto A; Baba H
    Am J Surg; 2018 Jul; 216(1):111-115. PubMed ID: 28859917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
    Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
    Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.